Intensity Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$11.2MTTM through 30 Jun 2026
Free Cash Flow -$9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-97.7%ROE
-82.3%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio5.92x
Net Debt-$11.8Mnet cash position
Cash & Equivalents$9.5M
Quality Metrics
Altman Z-Score-9.14
Piotroski F-Score3 / 9
Earnings-Beat Rate66.7%
Multi-Year Trend
Diluted EPS-$2.00TTMFY2025: $-8.56
Dividend
No dividend
Capital Allocation
R&D Spend$6.1M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Clinical-Stage Biotechnology | $0 | View detailsThe company plans to resume patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study using capital raised in 2025 and its unused ATM facility. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.